1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Mystery Surrounds Pliant IPF Trial Pause As Stock Sinks

 
• By Kevin Grogan

The US company has voluntarily halted enrolment in BEACON-IPF of bexotegrast on the recommendation of the trial’s independent data safety monitoring board, leaving analysts puzzled over the drug's prospects for the lung disease.

pill pause
• Source: Nieslen Hobbs; the Pink Sheet | Shutterstock images

Pliant Therapeutics' plans for bexotegrast are up in the air after the company voluntarily paused elements of a Phase IIb/III trial of the idiopathic pulmonary fibrosis (IPF) drug on the less-than-clear recommendation of a data safety monitoring board (DSMB).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

More from Therapy Areas

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.